A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge

The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 ade...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shipo, Zhong, Gongxun, Zhang, Jun, Shuai, Lei, Zhang, Zhe, Wen, Zhiyuan, Wang, Busen, Zhao, Zhenghao, Song, Xiaohong, Chen, Yi, Liu, Renqiang, Fu, Ling, Zhang, Jinlong, Guo, Qiang, Wang, Chong, Yang, Yilong, Fang, Ting, Lv, Peng, Wang, Jinliang, Xu, Junjie, Li, Jianmin, Yu, Changming, Hou, Lihua, Bu, Zhigao, Chen, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427994/
https://www.ncbi.nlm.nih.gov/pubmed/32796842
http://dx.doi.org/10.1038/s41467-020-17972-1
Descripción
Sumario:The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.

Ejemplares similares